This study is currently not recruiting participants.

Bicalutamide as an Androgen Blocker with Secondary Effect of Promoting Feminization in Male to Female (MTF) Transgender Adolescents

Investigating the Use of Investigational Hormone Therapy in MTF Transgender Patients

Not Recruiting
100 years or below
All
Phase N/A

Brief description of study.

The primary purpose of this study is to characterize the use of bicalutamide in MTF transgender patients followed in the pediatric endocrine clinic at Riley Hospital for Children.

Detailed description of study

The primary purpose of this study is to characterize the use of bicalutamide in MTF transgender patients followed in the pediatric endocrine clinic at Riley Hospital for Children.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Healthy
  • Age: 100 years or below
  • Gender: All

The purpose of this study is to investigate the use of an investigational medication in male-to-female (MTF) transgender patients. These patients are followed in the pediatric endocrine clinic at Riley Hospital for Children. The study aims to understand how this medication is used in this specific group of patients.

Participants in this study will receive the investigational medication, and researchers will observe its effects. The study will take place in a clinical setting, where healthcare professionals will monitor the patients' responses to the treatment.

  • Who can participate: The study is open to MTF transgender patients aged X-Y who are being followed in the pediatric endocrine clinic at Riley Hospital for Children.
  • Study details: Participants will receive the investigational medication and will be monitored by healthcare professionals. A placebo will not be used in this study.
Updated on 19 Feb 2024. Study ID: 1712490929

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team